The collaboration will involve the permanent presence of a Farminerva S.r.l. section on the science park, and will join two other biotechnology companies present there (LayLine Genomics and BioLab). Effort will be dedicated to accelerating domestic and international partnerships to in-license or co-develop new intellectual property with the aim to move the development as far as possible up the biomedical product value chain, prior to out-licensing for significant value creations.
Fondazione Parco Biomedico San Raffaele (PSB)
Located approximately 15 km south of Rome in a natural reserve, the science park was created by the Banca di Roma, the Chamber of Commerce of Rome, and the Fondazione San Raffaele Monte Tabor in response to the recognised need to have a biomedical research centre in the Lazio region. Opened in 2002, the park is now home to 3 companies and 9 research groups from Universities and centres working in: Stem cells, Oncology, leukaemia and Immunology; Molecular cardiology; Skeletal regeneration; Cell therapy and tissue engineering; Muscular dystrophies; Biomedical quality control; Neurological Disorders and Diabetes. The infrastructure permits the development of concept to preclinical development based on the state-of-the-art facilities including a animal facility encompassing conventional and SPF small animals and a large animal surgery unit.
Farminerva is a private company, founded in 2006, focused on research activities to reach new advanced solutions in biomedical sector. These objectives are developed by a strong cooperation with academic and institutional centres, as the Fondazione Parco Biomedico San Raffaele and CRISC of the Rome University, where Farminerva sponsors the execution of all preclinical and clinical studies requested by local regulatory authorities to obtain marketing license.
This collaboration defines a platform which promotes and coordinates research projects from preclinical to clinical phases to improve specific knowledge in two particular field: the first one concerns new products useful in early diagnosis of orthopaedic, cardiovascular, bone tissue inflammatory and/or infective based diseases, diabetic and oncological diseases. Further effort will be targeted on developing drugs for treatment of infective, diabetic and oncological diseases.
The other one aims to discovery new therapeutic indication of generic drugs to treat neurological, psychiatric and abuse disorders (second/other medical use), through the participation of CNR IASI researchers which perform advanced statistical analysis on large database (1/3 million of subjects) to identify co-morbidity data of relevant clinic interest.
About 50 free lance professionals work in Farminerva projects to ensure high quality level in management and monitoring activities and significantly shorter time to achieve the marketing phase.
Jonathan Dando | alfa
28.06.2017 | Technische Universität München
For a chimpanzee, one good turn deserves another
27.06.2017 | Max-Planck-Institut für Mathematik in den Naturwissenschaften (MPIMIS)
19.06.2017 | Event News
13.06.2017 | Event News
13.06.2017 | Event News
28.06.2017 | Awards Funding
28.06.2017 | Earth Sciences
28.06.2017 | Physics and Astronomy